This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Management

Authoring team

Lifestyle Advice

  • insufficient evidence to recommend any particular lifestyle advice
    • smokers should be advised not to smoke for general health reasons and healthy eating should be encouraged, though neither are known to affect these symptoms

Pharmacological interventions

  • H Pylori eradication - it is recommended H Pylori eradication is used in this condition in keeping with the test and treat strategy.
  • antisecretory treatments
    • RCTs have demonstrated small but significant benefits of PPI or H2 receptor antagonist use. Responses are best if dyspepsia is "ulcer-like" or reflux type
    • recommended that antisecretory treatment be considered of potential use in this condition
  • stop NSAIDs if possible and consider other drugs as provoking agents
  • repeat investigations if serious symptoms develop (e.g. alarm symptoms)

Guidance as to the step-by-step management of non-ulcer dyspepsia has now been provided by NICE (see linked item).

Notes:

  • a systematic review revealed that there is evidence that anti-secretory therapy (H2 receptor antagonists, proton pump inhibitors) may be effective in NUD

Reference:

  1. BSG (2002). Dyspepsia management guidelines.
  2. Moayyedi P et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001960. Review.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.